13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001892134
Total reported value
$4.6B
$4.6B
49 檔
19.5%
According to the latest 13F quarterly dataset, Frazier Life Sciences Management, L.P. managed an equity portfolio of $4.6B at the end of Q2 2024, spanning 49 distinct U.S. exchange-listed positions.
During Q2 2024, Frazier Life Sciences Management, L.P.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 10.99% | -0.61% | — | |
| 2 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 10.39% | +1.33% | — | |
| 3 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 8.49% | +0.70% | — | |
| 4 | ✓ | Hillevax Inc | Stock-Other | 7.18% | — | +8.54% | |
| 5 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 4.87% | -0.61% | — | |
| 6 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.55% | — | +8.27% | |
| 7 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 4.30% | -4.08% | +6.35% | |
| 8 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 3.82% | -0.35% | — | |
| 9 | IRON | Disc Medicine Inc | Stock-Other | 3.70% | -0.07% | +123.55% | |
| 10 | PCVX | Vaxcyte Inc | Stock-Other | 3.67% | — | -8.78% | |
| 11 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 3.14% | — | +12.94% | |
| 12 | ANAB | Anaptysbio Inc | Stock-Other | 2.54% | — | +140.70% | |
| 13 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.24% | — | +9.95% | |
| 14 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.03% | -2.57% | EXIT | |
| 15 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 2.02% | -0.32% | -11.19% | |
| 16 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.81% | -1.69% | EXIT | |
| 17 | ERAS | Erasca Inc | Stock-Other | 1.79% | -0.31% | — | |
| 18 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.76% | -1.09% | EXIT | |
| 19 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.67% | — | — | |
| 20 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.57% | — | — | |
| 21 | SVRA | Savara Inc | Stock-Other | 1.54% | -0.07% | +103.93% | |
| 22 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.37% | — | — | |
| 23 | CGON | Cg Oncology Inc | Stock-Other | 1.14% | — | — | |
| 24 | PEPG | Pepgen Inc | Stock-Other | 1.12% | — | — | |
| 25 | ✓ | Merus N V | Stock-Other | 1.03% | — | -50.02% | |
| 26 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.03% | +0.99% | — | |
| 27 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.02% | — | — | |
| 28 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.82% | — | — | |
| 29 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.75% | — | — | |
| 30 | CERE1EUR | Cerevel Therapeutics Holding | Stock-Other | 0.75% | — | — | |
| 31 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.74% | — | — | |
| 32 | ✓ | Immatics NV | Stock-Other | 0.63% | — | — | |
| 33 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.62% | — | — | |
| 34 | MGNX | Macrogenics Inc | Stock-Other | 0.60% | — | +21.81% | |
| 35 | APLT | Applied Therapeutics Inc | Stock-Other | 0.50% | — | +17.07% | |
| 36 | PBYI | Puma Biotechnology Inc | Stock-Other | 0.47% | — | +8.74% | |
| 37 | ETNBGBP | 89bio Inc | Stock-Other | 0.37% | — | — | |
| 38 | ✓ | Elevation Oncology Inc | Stock-Other | 0.37% | — | — | |
| 39 | COGT | Cogent Biosciences Inc | Stock-Other | 0.37% | — | — | |
| 40 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.36% | -0.03% | — | |
| 41 | ARVN | Arvinas Inc | Stock-Other | 0.36% | — | — | |
| 42 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.34% | — | — | |
| 43 | ALLO | Allogene Therapeutics Inc | Stock-Other | 0.31% | +0.78% | — | |
| 44 | ANTX | An2 Therapeutics Inc | Stock-Other | 0.21% | — | +50.40% | |
| 45 | ✓ | Newamsterdam Pharma Company | Stock-Other | 0.20% | -0.03% | — | |
| 46 | DSGN | Design Therapeutics Inc | Stock-Other | 0.19% | +0.57% | NEW | |
| 47 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.17% | -0.04% | — | |
| 48 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 0.05% | — | -11.95% | |
| 49 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.01% | +0.09% | — |
According to official SEC Form 13F filings, Frazier Life Sciences Management, L.P. reported a total U.S. public equity portfolio value of $4.6B across 49 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NAMS, MIRM, KRYS) accounted for 19.5% of total reported equity market value during Q2 2024.
During Q2 2024, Frazier Life Sciences Management, L.P.'s top holdings by market value included NAMS (11.0%)、MIRM (10.4%)、KRYS (8.5%). The largest single position, NAMS, represented 11.0% of total portfolio value.
In Q2 2024, Frazier Life Sciences Management, L.P. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.